13 February 2025
PRESS RELEASE
Copenhagen, 13 February 2025
The Danish nutrition company NUPO has made a multi-million DKK investment in fellow Danish tech firm Liva Healthcare A/S. This investment has in turn been used to acquire a stake in Discover Momenta, a UK-based company that currently holds a third of the market for type 2 diabetes treatment in England. The move will allow NUPO to add a double-digit million DKK figure to its top line already this year.
Most Danes are likely familiar with NUPO from supermarket shelves, where its weight management products have long been a staple. However, NUPO products are also widely used in clinical settings within Denmark’s public healthcare system, as well as in weight loss and treatment clinics around the world.
When it comes to managing type 2 diabetes, medication is still the most common route. But pharmacological treatment is not the only way forward. In several countries, NUPO’s products are already included in clinical trials focused on remission-based approaches to type 2 diabetes—with promising results to date.
Low-calorie diets helping patients live symptom-free
The NHS in England has successfully rolled out the Path to Remission programme across all 42 regions following a highly effective trial period. The programme guides patients through a structured process that begins with a 12-week low-calorie diet. The goal is to bring long-term blood sugar levels back to normal ranges and maintain a symptom-free life—without medication.
NUPO’s investment in Discover Momenta provides direct access to this fast-growing segment. Momenta currently holds 13 of the 42 regional NHS contracts, opening the door for NUPO to help thousands of patients—and reinforce the role of low-calorie diets as an effective solution for type 2 diabetes care.
A major cost burden for the Danish healthcare system
The NHS has already identified significant potential in the use of low-calorie diets, which stands in stark contrast to the Danish health authorities’ continued focus on symptom management primarily through medication. Type 2 diabetes treatment costs the Danish healthcare system billions each year, and in 2024, the number of newly diagnosed patients reached an all-time high.
Peter Wedelheim, CEO of NUPO, sees great potential in both the UK and Danish markets:
“Our ownership in Liva Healthcare has paved the way for this partnership with Discover Momenta in the UK, giving us access to a market that will contribute a double-digit million DKK revenue increase annually—and making the UK our largest export market.
Most importantly, we now have the opportunity to show that a low-calorie diet, combined with lifestyle interventions, is a highly effective and accessible option for patients with type 2 diabetes. It enables patients to live virtually symptom-free while potentially saving billions in public health costs related to medication, treatment, care, and lost productivity,” says Peter Wedelheim, who has led NUPO A/S since 2017.
He adds:
“Like the health authorities in England, we hope more countries—Denmark included—will follow suit as the evidence continues to grow. Type 2 diabetes is a serious condition that affected over 30,000 Danes last year alone, often resulting in reduced quality of life. That’s why we’re strong advocates for remission-focused approaches that include a low-calorie diet and guidance from a clinical dietitian.
The more patients the NHS guides through this programme, the clearer the case becomes for this type of treatment.”
Up to 70% achieve remission
Through its contracts with NHS regions, Discover Momenta treats approximately 5,000 to 6,000 new patients annually. Of these, 60–70% achieve remission after 12 months—replacing a life of medication and complications with one that is largely free from symptoms.
The remission programmes begin with a low-calorie diet in the first 12 weeks of a 12-month intervention. This helps bring long-term blood glucose levels in line with healthy individuals. While remission is not the same as a cure, patients remain symptom-free and can live a near-normal life—without relying on medication.
For further information, please contact:
Press contact: Jacob Lange, Lange PR
+45 20 76 30 20 / jacob@langepr.dk
About NUPO
NUPO is a Danish company with over 40 years of experience in health and nutrition. The company is known for its scientifically documented weight loss products, developed by Dr. Flemming Quaade in collaboration with healthcare professionals at Hvidovre Hospital.
NUPO offers a wide range of products, including total diet replacements, meal replacements, snacks, and supplements—designed to make weight loss and weight maintenance easier and more accessible.
The company is headquartered in Brøndby and posted a nine-figure DKK revenue last year.
More at: https://www.nupo.com
About Liva Healthcare
Liva Healthcare is a digital health provider offering a high-tech platform combined with human-led, AI-assisted therapeutic lifestyle interventions to manage chronic lifestyle-related conditions such as prediabetes, type 2 diabetes, obesity, cardiovascular disease, and hypertension.
By integrating digital tracking of key health indicators with behavioural coaching, Liva ensures lasting patient engagement and sustainable lifestyle changes in areas such as nutrition, exercise, sleep, and mental well-being.
With over 80,000 patients treated through partnerships—including with the NHS—Liva provides a scalable, evidence-based solution for long-term chronic disease management.
More at: https://www.livahealthcare.com
About Discover Momenta
Discover Momenta is a leading developer and provider of evidence-based lifestyle health programmes. The company designs, delivers, licenses, and continually improves services that help individuals overcome everyday barriers to healthier living.
Its programmes equip organisations and staff with the tools needed to help participants achieve measurable health improvements.
Discover Momenta offers a broad range of services—from short-term interventions to intensive behavioural change programmes—aimed at driving long-term, cost-effective health outcomes.
The company collaborates with public, private, and voluntary sector organisations to deliver community-based interventions.
Momenta’s development team—comprising behavioural scientists, clinicians, and subject matter experts—continuously refines its programmes. Its scalable approach allows for international reach while remaining adaptable to local needs.
More at: https://discovermomenta.com
